Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-02-13
2000-04-04
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546133, 546217, 548544, A61K 31445
Patent
active
060462132
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention is directed to neuroprotective (antiischemic and excitatory aminoacid receptor blocking) phenol derivatives defined by the formula (I) below; pharmaceutically acceptable salts thereof; pharmaceutical compositions thereof; a method of using these compounds in the treatment of neurological disorders, including anxiety, cerebral ischemia, epilepsy, muscular spasms and stroke; and a method of using these compounds in the treatment of CNS degenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease. The present invention is further directed to a method of using these compounds in the treatment of drug addiction, migraine and urinary incontinence. The present invention is still further directed to a method of using these compounds in the treatment of traumatic brain injury.
The excitatory amino acids are an important group of neurotransmitters that mediate excitatory neurotransmission in the central nervous system. Glutamic acid and aspartic acid are two endogenous ligands that activate excitatory amino acid (EAA) receptors. There are two types of EAA receptors, ionotropic and metabotropic, which differ in their mode of signal transduction. There are at least three distinct ionotropic EAA receptors characterized by the selective agonist that activates each type: the NMDA, (N-methyl-D-aspartic acid), the AMPA (2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid), and the kainic acid receptors. The ionotropic EAA receptors are linked to ion channels that are permeable to sodium and, in the case of NMDA receptors, calcium. Metabotropic receptors, linked to phosphoinositide-hydrolysis by a membrane associated G-protein, are activated by quisqualic acid, ibotenic acid, and (1S,3R)-1-aminocyclopentane 1,3-dicarboxylic acid.
The NMDA receptor is a macromolecular complex consisting of a number of distinct binding sites that gate an ion channel permeable to sodium and calcium ions. Hansen and Krogsgaard-Larson, Med. Res. Rev., 10, 55-94 (1990). There are binding sites for glutamic acid, glycine, and polyamines, and a site inside the ion channel where compounds such as phencyclidine (PCP) exert their antagonist effects.
Competitive NMDA antagonists are compounds which block the NMDA receptor by interacting with the glutamate binding site. The ability of a particular compound to competitively bind to the NMDA glutamate receptor may be determined using a radioligand binding assay. See Murphy et al., British J. Pharmacol. 95, 932-938 (1988). The antagonists may be distinguished from the agonists using a rat cortical wedge assay. See Harrison and Simmonds, British J. Pharmacol., 84, 381-391 (1984). Examples of competitive NMDA antagonists include D-2 amino 5-phosphonopentanoic acid (D-AP5), and D-2-amino-7-phosphonoheptanoic acid, Schoepp et al., J. Neur. Transm., 85, 131-143 (1991).
Antagonists of neurotransmission at NMDA receptors are useful therapeutic agents for the treatment of neurological disorders. U.S. Pat No. 4,902,695 is directed to series of competitive NMDA antagonists useful for the treatment of neurological disorders, including epilepsy, stroke, anxiety, cerebral ischemia, muscular spasms, and neurodegenerative disorders such as Alzheimer's disease and Huntington's disease. U.S. Pat. No. 4,968,878 is directed to a second series of competitive NMDA receptor antagonists useful for the treatment of similar neurological disorders and neurodegenerative disorders. U.S. Pat. No. 5,192,751 provides a method of treating urinary incontinence in a mammal which comprises administering an effective amount of a competitive NMDA antagonist.
NMDA antagonists are also useful therapeutic agents with anticonvulsant, anxiolytic, muscle relaxant, and antipsychotic activity. J. Lehman, The NMDA Receptor, Drugs of the Future, 14, No. 11, p. 1059 (1989). NMDA antagonists have also been reported to be effective for treating migraine (Canadian Journal of Neurological Science, 19(4), p. 487 (1992)); drug addiction (Science, 251, p. 85 (1991)); an
REFERENCES:
patent: 3294804 (1966-12-01), Carabateas
patent: 3509164 (1970-04-01), Carron
patent: 3591593 (1971-07-01), Thiel et al.
patent: 4902695 (1990-02-01), Ornstein
patent: 4968678 (1990-11-01), Ornstein
patent: 5185343 (1993-02-01), Chenard
patent: 5192751 (1993-03-01), Thor
patent: 5272160 (1993-12-01), Chenard
patent: 5306723 (1994-04-01), Chenard
patent: 5338754 (1994-08-01), Chenard
patent: 5352683 (1994-10-01), Mayer et al.
patent: 5356905 (1994-10-01), Butler
patent: 5455250 (1995-10-01), Chenard
patent: 5620990 (1997-04-01), Thenot et al.
Hansen, et al., Med. Res. Rev., 1990, 10, 55-94.
Murphy et al., British J. Pharmacol., 1988, 95, 932-938.
Harrison et al., British J. Pharmacol., 1984, 84, 381-391.
Schoepp et al., J. Neur. Transm. 1991, 85, 131-143.
Lehman, Drugs of the Future, 1984, 14, 1059.
Trujillo et al., Science, 1991, 251, 85-87.
PIPS, 1990, 111, 1-3.
Carron et al., Drug. Res. 1971, 21, 1992-1999.
Gotti et al., J. Pharm. Exp. Ther., 1988, 247, 1211-1221.
Carter, J. Pharm. Exp. Ther., 1988, 247, 1222-1232.
Ferreyra-Moyano, H. et al., Int. J. Neurosci., 1989, 49 (3-4), 157-197.
Olney, J. W., Prog. Brain Res., 1990, 86, 37-51.
Choi, Neuron, 1988, 1, 623-634.
Butler Todd W.
Chenard Bertrand L.
Benson Gregg C.
Chang Ceila
Pfizer Inc.
Richardson Peter C.
Ronau Robert T.
LandOfFree
Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365598